Sagimet Biosciences, Inc. (SGMT)
10.80
-0.29
(-2.61%)
USD |
NASDAQ |
Sep 21, 16:00
10.80
0.00 (0.00%)
After-Hours: 20:00
Sagimet Biosciences Shareholders Equity (Quarterly) : 256.16M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 256.16M |
| March 31, 2026 | 102.46M |
| December 31, 2025 | 111.38M |
| September 30, 2025 | 119.26M |
| June 30, 2025 | 130.16M |
| March 31, 2025 | 138.99M |
| December 31, 2024 | 155.80M |
| September 30, 2024 | 170.68M |
| June 30, 2024 | 183.29M |
| March 31, 2024 | 190.02M |
| December 31, 2023 | 91.06M |
| Date | Value |
|---|---|
| September 30, 2023 | 97.88M |
| June 30, 2023 | 16.21M |
| March 31, 2023 | 21.92M |
| December 31, 2022 | |
| September 30, 2022 | |
| June 30, 2022 | |
| March 31, 2022 | |
| December 31, 2021 | |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | 74.04M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 1.307B |
| Alnylam Pharmaceuticals, Inc. | 1.354B |
| Anika Therapeutics, Inc. | 137.28M |
| Savara, Inc. | 143.66M |
| Vericel Corp. | 370.04M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 263.43M |
| Total Liabilities (Quarterly) | 7.275M |
| Debt to Equity Ratio | 0.0076 |
| Current Ratio | 44.94 |
| Net Debt Paydown Yield | -0.08% |